Roche struck a deal to buy Saga Diagnostics for up to $595 million, and Foundation Medicine is set to expand its molecular residual disease (MRD) offering through the acquisition of Saga’s Pathlight platform. The planned close is targeted for Q3 2026, pending regulatory approvals. Pathlight combines whole genome sequencing (WGS) and digital PCR to detect and track structural variants with ultra-sensitive precision. Foundation Medicine plans to integrate Pathlight into its diagnostic portfolio and broaden its use across additional tumor types beyond current breast and colorectal applications. Roche and Foundation also outlined plans for technology collaboration, including leveraging Roche’s AXELIOS sequencing platform and Digital LightCycler PCR to pursue a decentralized MRD solution aimed at improving patient access across healthcare settings.